Results from CHAMPION-NMOSD trial demonstrated ULTOMIRIS reduced the risk of relapse in AQP4 Ab+ NMOSD by 98.6% compared to placebo ULTOMIRIS also showed a lower proportion of patients experiencing ...

– Company will conduct further analysis of trial data to determine next steps – – No new safety findings were observed for ULTOMIRIS use in COVID-19 – BOSTON--(BUSINESS WIRE)-- Alexion Pharmaceuticals ...

Results from the trial were presented on April 5 at the 2022 American Academy of Neurology (AAN) Annual Meeting. gMG is a rare, debilitating, chronic, autoimmune neuromuscular disease that leads to a ...

BOSTON -- (EUREKALERT!) -- Alexion Pharmaceuticals, Inc. today announced the first conference presentation of the topline Phase 3 data for ULTOMIRIS ® (ravulizumab), the first and only long-acting C5 ...

Dublin, April 13, 2023 (GLOBE NEWSWIRE) -- The "ULTOMIRIS Market Drug Insight and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering. The report provides comprehensive ...

Positive high-level results from the open-label Phase III CHAMPION-NMOSD trial showed that ULTOMIRIS ® (ravulizumab-cwvz) achieved a statistically significant and clinically meaningful reduction in ...

BOSTON– (BUSINESS WIRE)–Jul 15, 2021– Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced positive topline results from a Phase 3 study evaluating the safety and efficacy of ULTOMIRIS (R) ...

WILMINGTON, Del., March 25, 2024--(BUSINESS WIRE)--ULTOMIRIS ® (ravulizumab-cwvz) has been approved in the United States (US) as the first and only long-acting C5 complement inhibitor for the ...